Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00574769
Recruitment Status : Completed
First Posted : December 17, 2007
Last Update Posted : April 11, 2017
Genentech, Inc.
Information provided by (Responsible Party):
University of Southern California

Brief Summary:
Prostate cancer is a common and important health issue. Although effective treatment is often available for localized disease, metastatic prostate cancer remains incurable. The initial treatment for metastatic prostate cancer often includes medical or surgical treatments that deprive the tumor of male hormones (androgens) required for growth. Although this treatment is successful for many patients, the cancer may eventually return in others. Recurrent prostate cancer may be treated with additional hormonal agents, but these agents usually do not result in long-term control of the disease. Eventually most patients with recurrent prostate cancer progress to a state where the cancer grows despite very low level of circulating male hormones known as androgen independent prostate cancer (AIPC).

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: RAD001, Docetaxel, Bevacizumab Phase 1 Phase 2

Detailed Description:
Patients will undergo a screening procedure to determine eligibility of trial. During the treatment period, the patient will be given docetaxel/bevacizumab on day 1 followed by RAD001 continuously on days 2-21 and this is called a treatment cycle. Patients will be able to continue to receive multiple treatment courses as long as the cancer does not get worse and the person does not develop other problems that would prevent him from staying in the study. The final part of the research is the study completion period which includes an end of treatment visit and subsequent follow-up visits. These visits take place whenever the research medication is stopped, even if it is stopped early. For the patient's safety, he/she should at least complete the end of treatment visit.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 27 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase Ib/II Evaluation of RAD001 With Docetaxel and Bevacizumab in Patients With Metastatic Androgen Independent Prostate Cancer
Actual Study Start Date : February 17, 2010
Actual Primary Completion Date : February 17, 2016
Actual Study Completion Date : February 17, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: 1 Drug: RAD001, Docetaxel, Bevacizumab

RAD001 oral, 2.5 mg daily RAD001 oral, 5mg daily

Bevacizumab infusion (IV), 15 mg/kg every 21 days

Docetaxel infusion (IV), 75 mg/m^2 every 21 days

Other Names:
  • everolimus
  • Avastin
  • Taxotere

Primary Outcome Measures :
  1. Establish a maximal tolerated or optimal biologic dose of RAD001 in combination with docetaxel/bevacizumab [ Time Frame: After the last patient in the cohort has completed at least two cycles of RAD001/docetaxel/bevacizumab ]

Secondary Outcome Measures :
  1. Evaluate the efficacy of RAD001 in combination with docetaxel/bevacizumab as determined by best overall response and progression-free survival in patients with advanced prostate cancer. [ Time Frame: overall survival ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age ≥ 18 years.
  • Signed informed consent
  • ECOG performance status: 0-2
  • Histologically documented adenocarcinoma of the prostate
  • Progressive disease despite androgen deprivation therapy. Progressive disease is defined as any one of the following:
  • Measurable Disease: Objective evidence of increase > 20% in the sum of the longest diameters of target lesions from the time of maximal regression or the appearance of one or more new lesions (Modified RECIST Criteria)
  • Bone Scan Progression: Appearance of one or more new lesions on bone scan attributable to prostate cancer
  • PSA Progression: An elevated PSA (≥ 5 ng/ml) which has risen serially from baseline on two occasions each at least one week apart
  • At least 4 weeks since any other hormonal therapy. Flutamide and megestrol acetate (any dose) must be discontinued at least 4 weeks prior to initiating treatment. Bicalutamide or nilutamide must be discontinued at least 6 weeks prior to initiating treatment. If improvement following antiandrogen withdrawal is noted, progression must be established using the criteria above. Androgen suppression should be continued
  • ≥ 4 weeks since major surgery and fully recovered
  • ≥ 8 weeks since high risk surgery and fully recovered
  • ≥ 4 weeks since any prior radiation and fully recovered
  • ≥ 6 weeks since the last dose of bone targeted radiopharmaceutical
  • Men of child-bearing potential are required to use an effective means of contraception
  • Required Initial Laboratory Values:

    • ANC ≥ 1500/µL
    • Platelet count ≥ 100,000/µL
    • Creatinine ≤ 1.5 x ULN
    • Bilirubin ≤ 1.5 x ULN
    • AST ≤ 1.5 x ULN
    • Urine protein to creatinine ratio < 1.0
    • Serum Testosterone ≤ 50 ng/dL (For patients who have not had bilateral orchiectomy.)

Exclusion Criteria:

  • Prior treatment with cytotoxic chemotherapy for metastatic disease
  • Prior treatment with anti-angiogenic agents, including thalidomide and bevacizumab
  • Prior treatment with any investigational drug within 4 weeks of initiating treatment
  • Prior treatment with an mTor inhibitor
  • Chronic treatment with systemic steroids or another immunosuppressive agent
  • Known history of HIV seropositivity
  • Known brain metastases (brain imaging is not required)
  • Congestive heart failure
  • Uncontrolled hypertension. Patients with history of hypertension must be well controlled (< 150/100) on a regimen of anti-hypertensive therapy
  • Any prior history of hypertensive crisis or hypertensive encephalopathy
  • Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001
  • History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment
  • Active bleeding diathesis or on oral anti-vitamin K medications (except low dose coumarin)
  • Arterial thrombotic events, including transient ischemic attack (TIA), cerebrovascular accident (CVA), at any time
  • History of unstable angina or angina requiring surgical or medical intervention in the past 12 months, or myocardial infarction (MI)
  • Patients with clinically significant peripheral artery disease or any other arterial thrombotic event
  • Significant vascular disease
  • Other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study
  • Proteinuria at screening as demonstrated by either
  • Urine protein:creatinine (UPC) ratio ≥ 1.0 OR
  • Urine dipstick for proteinuria ≥ 2+
  • Serious or non-healing wound, ulcer or bone fracture
  • Peripheral neuropathy ≥ grade 2
  • Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
  • Herbal medications and food supplements must be discontinued before registration. Patients may continue on daily vitamins and calcium supplements
  • History of noncompliance to medical regimens
  • Unwilling to or unable to comply with the protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00574769

United States, California
Westside Prostate Cancer Center, University of Southern California
Beverly Hills, California, United States, 90211
USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
Sponsors and Collaborators
University of Southern California
Genentech, Inc.
Principal Investigator: Mitchell E Gross, MD, Ph.D University of Southern California

Responsible Party: University of Southern California Identifier: NCT00574769     History of Changes
Other Study ID Numbers: 4P-09-4
First Posted: December 17, 2007    Key Record Dates
Last Update Posted: April 11, 2017
Last Verified: April 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by University of Southern California:
mTOR inhibition
adenocarcinoma of the prostate
recurrent prostate cancer
stage IV prostate cancer
prostate cancer
Metastatic, androgen independent prostate cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Hormones, Hormone Substitutes, and Hormone Antagonists
Immunosuppressive Agents
Immunologic Factors
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents